Stock INDP INDAPTUS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Indaptus Therapeutics, Inc.

Equities

INDP

US45339J1051

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
2.11 USD -3.21% Intraday chart for Indaptus Therapeutics, Inc. -10.59% +19.89%
Mar. 14 Top Premarket Gainers MT
Mar. 13 Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Evolution of the average Target Price on Indaptus Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

007ff6328103a7dee4b630eda20.epkgyZIWTd9NJPlRCPaW7WJO_Vh1vsKENgbXHFCoL48.FdBG-MVxOOh8SbhmUbjHj1cPkQcd4Z3hQU6QSh-YS6I_xnSj2EY0inRxtA~db6543bba491c8c178ae0bc5a1975b06

Analyst Recommendations on Indaptus Therapeutics, Inc.

HC Wainwright Adjusts Price Target on Indaptus Therapeutics to $12 From $15, Maintains Buy Rating MT
HC Wainwright Reiterates Indaptus Therapeutics at Buy With $15 Price Target MT
HC Wainwright Upgrades Indaptus Therapeutics to Buy From Neutral, Sets $15 Price Target MT
INDAPTUS THERAPEUTICS : Maxim Group Upgrades Indaptus Therapeutics to Buy Rating From Hold, Sets $16 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.11 USD
Average target price
10 USD
Spread / Average Target
+373.93%
High Price Target
12 USD
Spread / Highest target
+468.72%
Low Price Target
8 USD
Spread / Lowest Target
+279.15%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Indaptus Therapeutics, Inc.

HC Wainwright
Maxim

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. INDP Stock
  4. Consensus Indaptus Therapeutics, Inc.